Varenicline Tartrate
Parkinsonism
Corporal Michael J. Crescenz VA Medical CenterPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Parkinsonism cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate California Pacific Medical Center Research Institute | Phase 4 | BB |
IOFLUPANE Mayo Clinic | Phase 4 | BB |
Meta-Iodobenzylguanidine Mayo Clinic | Phase 4 | BB |
Zonisamide The Cooper Health System | Phase 4 | B |
Droxidopa The Cooper Health System | Phase 4 | B |
ub-312 United Neuroscience Ltd. | Phase 1 | CC |
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Indonesia University | N/A | D |
Ramelteon Northwestern University | N/A | D |
Same molecule, other indications
Varenicline Tartrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →